Who owns SYROS PHARMACEUTICALS INC?
- Ticker: SYRS
- CUSIP Number: 87184q206
Tip: Access positions for across all investors
Analyze quarterly positions in Syros Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Syros Pharmaceuticals stock
Who bought or sold SYROS PHARMACEUTICALS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors | 2.7M | $15M | 29% | Mar 2024 |
|
| Artal Group | 2.5M | $13M | 0% | Mar 2024 |
|
| Adage Capital Partners GP | 2.1M | $11M | 187% | Mar 2024 |
|
| Samsara BioCapital | 1.8M | $9.6M | 0% | Mar 2024 |
|
| Avidity Partners Management | 1.7M | $9.0M | 0% | Mar 2024 |
|
| Point72 Asset Management | 1.5M | $7.9M | 0% | Mar 2024 |
|
| Flagship Ventures Management | 1.3M | $6.9M | 0% | Mar 2024 |
|
| Vanguard Group | 928k | $5.0M | 21% | Mar 2024 |
|
| Opaleye Management | 788k | $4.2M | 119% | Mar 2024 |
|
| Goldman Sachs Group | 447k | $2.4M | 86% | Mar 2024 |
|
| Kennedy Capital Management | 405k | $2.2M | 100% | Mar 2024 |
|
| Blue Owl Capital Holdings | 341k | $1.8M | -77% | Mar 2024 |
|
| Walleye Trading Advisors | 285k | $1.5M | 100% | Mar 2024 |
|
| Millennium Management | 261k | $1.4M | 100% | Mar 2024 |
|
| BlackRock | 257k | $1.4M | 5% | Mar 2024 |
|
| Omega Fund Management | 251k | $2.0M | 0% | Dec 2023 |
|
| Geode Capital Management | 220k | $1.2M | 60% | Mar 2024 |
|
| UBS O'Connor | 175k | $936k | 100% | Mar 2024 |
|
| Jane Street | 173k | $923k | 716% | Mar 2024 |
|
| Assenagon Asset Management | 170k | $910k | 576% | Mar 2024 |
|
| Marshall Wace | 160k | $854k | 543% | Mar 2024 |
|
| ExodusPoint Capital Management | 155k | $829k | 43% | Mar 2024 |
|
| Qube Research & Technologies | 138k | $738k | 100% | Mar 2024 |
|
| DAFNA Capital Management | 136k | $727k | -37% | Mar 2024 |
|
| Perceptive Advisors | 117k | $625k | 100% | Mar 2024 |
|
| LPL Financial | 76k | $407k | -16% | Mar 2024 |
|
| Two Sigma Investments | 68k | $365k | 25% | Mar 2024 |
|
| Lgt Capital Partners | 55k | $294k | 0% | Mar 2024 |
|
| Bridgeway Capital Management | 52k | $276k | 30% | Mar 2024 |
|
| Man Group | 45k | $242k | 100% | Mar 2024 |
|
| Northern Trust | 37k | $195k | 40% | Mar 2024 |
|
| Bank of America Corporation | 34k | $181k | 237% | Mar 2024 |
|
| Citigroup | 34k | $180k | 100% | Mar 2024 |
|
| Balyasny Asset Management | 23k | $124k | 100% | Mar 2024 |
|
| T. Rowe Price Associates | 23k | $121k | 0% | Mar 2024 |
|
| 1492 Capital Management | 22k | $116k | 0% | Mar 2024 |
|
| Hrt Financial | 20k | $104k | 100% | Mar 2024 |
|
| Clarius | 19k | $100k | 0% | Mar 2024 |
|
| Y-Intercept | 19k | $99k | 100% | Mar 2024 |
|
| Morgan Stanley | 18k | $93k | 272% | Mar 2024 |
|
| Acadian Asset Management | 17k | $91k | 100% | Mar 2024 |
|
| Citadel Advisors | 17k | $90k | 3% | Mar 2024 |
|
| Brevan Howard Capital Management | 16k | $86k | 100% | Mar 2024 |
|
| CIBC Global Asset Management | 15k | $82k | 0% | Mar 2024 |
|
| HighTower Advisors | 15k | $80k | -1% | Mar 2024 |
|
| Squarepoint Ops | 15k | $80k | 100% | Mar 2024 |
|
| American Century Companies | 14k | $73k | 100% | Mar 2024 |
|
| Susquehanna International | 13k | $69k | -84% | Mar 2024 |
|
| Virtu Financial | 12k | $64k | 100% | Mar 2024 |
|
| CI Private Wealth | 12k | $64k | 0% | Mar 2024 |
|
| Two Sigma Advisers | 12k | $62k | 100% | Mar 2024 |
|
| XTX Topco | 11k | $59k | 100% | Mar 2024 |
|
| Integrated Wealth Concepts | 10k | $54k | 100% | Mar 2024 |
|
| Federation des caisses Desjardins du Quebec | 4.5k | $24k | 100% | Mar 2024 |
|
| Edmond De Rothschild Holding | 4.4k | $23k | 0% | Mar 2024 |
|
| Royal Bank of Canada | 1.3k | $6.0k | -56% | Mar 2024 |
|
| Pnc Financial Services | 1.1k | $5.9k | 0% | Mar 2024 |
|
| Advisor Group Holdings | 1.1k | $5.8k | 0% | Mar 2024 |
|
| Russell Investments | 750.00 | $4.0k | 0% | Mar 2024 |
|
| Rhumbline Advisers | 659.00 | $3.5k | 0% | Mar 2024 |
|
| Wells Fargo & Company | 617.00 | $3.3k | 14% | Mar 2024 |
|
| Jpmorgan Chase & Co | 549.00 | $2.9k | 0% | Mar 2024 |
|
| IFP Advisors | 438.00 | $3.4k | 0% | Dec 2023 |
|
| Simplex Trading | 232.00 | $999.989600 | 100% | Mar 2024 |
|
| Fifth Third Bancorp | 129.00 | $689.995200 | 0% | Mar 2024 |
|
| Tower Research Capital | 95.00 | $508.003000 | 100% | Mar 2024 |
|
| Sound Income Strategies | 76.00 | $407.002800 | 0% | Mar 2024 |
|
| FMR | 71.00 | $379.999100 | -79% | Mar 2024 |
|
| UBS Group | 21.00 | $111.999300 | 100% | Mar 2024 |
|
| PSI Advisors | 13.00 | $69.999800 | 0% | Mar 2024 |
|
| Steward Partners Investment Advisory | 8.00 | $43.000000 | 0% | Mar 2024 |
|
Who sold out of Syros Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| Tang Capital Management | Dec 2023 | 85k | $662k |
| 683 Capital Management | Dec 2023 | 36k | $284k |
| Group One Trading | Sep 2023 | 1.3k | $5.1k |